Diagnosis & Treatment of Splenic Marginal Zone Lymphoma

Introduction

Splenic marginal zone lymphoma (SMZL) is a rare subtype of non-Hodgkin lymphoma that primarily affects the spleen, bone marrow, and blood. Classified as an indolent (slow-growing) lymphoma, it often develops gradually over several years before causing noticeable symptoms. First identified in the 1990s, SMZL belongs to the marginal zone lymphoma group, which originates in marginal zone B-cells—a type of white blood cell essential to the immune system. This article provides a comprehensive overview of SMZL, including its risk factors, symptoms, diagnostic methods, treatment options, and strategies for managing symptoms at home. By understanding this condition, patients can make informed decisions about their health and work closely with healthcare providers to develop personalized treatment plans.

What is Splenic Marginal Zone Lymphoma?

Splenic marginal zone lymphoma (SMZL) is a slow-growing cancer that affects the spleen and the immune system. This article delves into its risk factors, symptoms, diagnostic tests, treatment approaches, and home care strategies to empower patients in managing their condition effectively.

Description of Splenic Marginal Zone Lymphoma

Splenic marginal zone lymphoma (SMZL) is a rare form of non-Hodgkin lymphoma that originates in marginal zone B-cells, which are located in the spleen. These B-cells play a critical role in the immune system by helping the body fight infections. In SMZL, these cells become cancerous and multiply uncontrollably, leading to an enlarged spleen (splenomegaly) and other complications. The disease primarily affects older adults, with the average age of diagnosis being around 65. Although SMZL progresses slowly, it can cause significant health challenges if left untreated.

SMZL often develops in stages. In its early stages, patients may not experience any symptoms, and the condition is frequently discovered incidentally during routine blood tests or imaging. As the disease advances, symptoms such as fatigue, abdominal discomfort, and recurrent infections may emerge. In some cases, SMZL can transform into a more aggressive form of lymphoma, necessitating intensive treatment.

Although rare, SMZL accounts for approximately 1-2% of all non-Hodgkin lymphomas. Due to its slow progression, many patients can live for years with appropriate treatment and regular monitoring. Early diagnosis and proactive management are crucial for preventing complications and improving quality of life.

Risk Factors for Developing Splenic Marginal Zone Lymphoma

Lifestyle Risk Factors

While lifestyle factors are not the primary cause of splenic marginal zone lymphoma, certain behaviors can influence overall immune health, indirectly affecting lymphoma risk. Chronic infections, particularly with the hepatitis C virus (HCV), are strongly associated with SMZL. Behaviors that increase the risk of HCV infection, such as intravenous drug use or unprotected sex, may also elevate the likelihood of developing SMZL. Additionally, smoking and excessive alcohol consumption can weaken the immune system, potentially increasing the risk of various cancers, including lymphomas.

Medical Risk Factors

Several medical conditions are linked to a higher risk of developing SMZL. Chronic infections, especially with hepatitis C, are strongly associated with this lymphoma. In some cases, treating the underlying hepatitis C infection can lead to remission of SMZL. Autoimmune disorders such as Sjögren’s syndrome or rheumatoid arthritis may also increase the risk of SMZL due to chronic inflammation and immune system dysregulation. Furthermore, individuals with a history of other lymphomas or blood cancers may face an elevated risk of developing SMZL.

Genetic and Age-Related Risk Factors

Age is a significant risk factor for SMZL, with most cases diagnosed in individuals over 60. As the immune system becomes less efficient with age, the likelihood of developing lymphomas like SMZL increases. While no specific genetic mutation has been directly linked to SMZL, a family history of lymphoma or other blood cancers may raise the risk. Certain genetic syndromes that affect the immune system, such as ataxia-telangiectasia, may also predispose individuals to lymphomas, including SMZL.

Clinical Manifestations of Splenic Marginal Zone Lymphoma

Fatigue

Fatigue is one of the most common symptoms of splenic marginal zone lymphoma, affecting 60-80% of patients. It is often caused by anemia, a condition in which the body lacks enough red blood cells to deliver oxygen to tissues. Lymphoma cells can infiltrate the bone marrow, reducing red blood cell production. Additionally, an enlarged spleen may destroy red blood cells more rapidly, exacerbating anemia and fatigue. Patients often feel persistently tired despite adequate rest, making daily activities more difficult.

Splenomegaly

Splenomegaly, or an enlarged spleen, occurs in nearly all SMZL patients. The spleen, a vital organ in the lymphatic system, becomes enlarged as lymphoma cells accumulate. This can cause discomfort or a sensation of fullness in the upper left abdomen. In severe cases, the spleen may press on nearby organs, such as the stomach, leading to early satiety (feeling full after eating small amounts). Splenomegaly is often one of the earliest signs of SMZL and can be detected during physical exams or imaging tests.

Weight Loss

Unintentional weight loss affects 30-40% of SMZL patients. This symptom may result from increased energy expenditure as the body fights the lymphoma, reduced appetite due to splenomegaly, or systemic effects of the disease. In advanced stages, the body may break down muscle and fat for energy, leading to noticeable weight loss.

Night Sweats

Night sweats, reported in 20-30% of SMZL patients, involve excessive sweating during sleep, often soaking bedclothes and sheets. Common in many lymphomas, night sweats may result from the immune system’s response to cancer. The release of chemicals like cytokines by lymphoma cells may disrupt the body’s temperature regulation, although the exact cause remains unclear.

Fever

Fever occurs in 10-20% of SMZL patients, typically presenting as a low-grade fever that may come and go. It is thought to result from the immune system’s response to lymphoma cells. In some cases, fever may indicate an infection, as SMZL patients are more susceptible to infections due to a weakened immune system. Persistent fever without an obvious cause should be evaluated by a healthcare provider.

Abdominal Pain

Abdominal pain, reported in 20-30% of SMZL patients, is often caused by splenomegaly. As the spleen enlarges, it can lead to discomfort or pain in the upper left abdomen. In some cases, this pain may radiate to the left shoulder, a phenomenon known as Kehr’s sign. The pain may worsen after eating, as the enlarged spleen presses on the stomach. In extreme cases, a significantly enlarged spleen may risk rupture, causing sudden, severe abdominal pain.

Lymphadenopathy

Lymphadenopathy, or swollen lymph nodes, occurs in 20-30% of SMZL patients. Lymph nodes, part of the lymphatic system, can become enlarged as lymphoma cells accumulate. This symptom is more common in advanced stages of SMZL and may be detected in the neck, armpits, or groin. Swollen lymph nodes may or may not be painful and can sometimes be felt during a physical exam.

Anemia

Anemia affects 50-60% of SMZL patients. It occurs when lymphoma cells infiltrate the bone marrow, reducing red blood cell production. Additionally, an enlarged spleen may destroy red blood cells more rapidly. Symptoms of anemia include fatigue, shortness of breath, dizziness, and pale skin. Anemia can significantly impact quality of life and may require treatment with blood transfusions or medications to stimulate red blood cell production.

Thrombocytopenia

Thrombocytopenia, or a low platelet count, affects 30-40% of SMZL patients. Platelets are essential for blood clotting, and a low count can lead to easy bruising, prolonged bleeding, and spontaneous bleeding from the gums or nose. Thrombocytopenia often results from bone marrow infiltration by lymphoma cells, reducing platelet production. Additionally, an enlarged spleen may sequester platelets, further lowering their count.

Increased Susceptibility to Infections

Increased susceptibility to infections affects 30-50% of SMZL patients. The spleen plays a vital role in filtering bacteria and pathogens from the blood. When it becomes enlarged or dysfunctional due to lymphoma, the body’s ability to fight infections is compromised. Additionally, SMZL can impair the bone marrow’s production of white blood cells, further weakening the immune response. Patients may experience frequent or severe infections, particularly respiratory infections.

Health Conditions with Similar Symptoms to Splenic Marginal Zone Lymphoma

Chronic Lymphocytic Leukemia (CLL)

Definition: Chronic lymphocytic leukemia (CLL) is a slow-progressing cancer of the blood and bone marrow, marked by the excessive production of abnormal white blood cells called lymphocytes. These cells accumulate in the blood, bone marrow, and lymphoid tissues, leading to symptoms such as persistent fatigue, swollen lymph nodes, and recurrent infections. CLL is most commonly diagnosed in older adults.

How to Differentiate CLL from Splenic Marginal Zone Lymphoma: Both CLL and splenic marginal zone lymphoma (SMZL) can cause fatigue, splenomegaly (enlarged spleen), and swollen lymph nodes. However, CLL often presents with more widespread and pronounced lymph node swelling, whereas SMZL primarily targets the spleen. Blood tests in CLL typically reveal a high count of abnormal lymphocytes, while in SMZL, these abnormal cells are more concentrated in the spleen and bone marrow. Flow cytometry can detect markers such as CD5 and CD23, which are characteristic of CLL but absent in SMZL. A bone marrow biopsy may also help confirm the diagnosis.

Follicular Lymphoma

Definition: Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that originates from B-lymphocytes. It commonly affects the lymph nodes but may also involve the bone marrow and spleen. Symptoms include painless lymph node swelling, persistent fatigue, night sweats, and unexplained weight loss.

How to Differentiate Follicular Lymphoma from Splenic Marginal Zone Lymphoma: Both follicular lymphoma and SMZL can cause enlarged lymph nodes, spleen, and fatigue. However, follicular lymphoma typically involves more widespread lymph node swelling, while SMZL primarily affects the spleen. Blood tests in follicular lymphoma may show fewer abnormalities compared to SMZL, where anemia or low platelet counts are more common. A biopsy can distinguish the two: follicular lymphoma exhibits clusters or “follicles” of abnormal B-cells, while SMZL shows a distinct cellular pattern in the spleen. Genetic testing may reveal BCL2 rearrangements in follicular lymphoma, which are absent in SMZL.

Marginal Zone Lymphoma (Other Types)

Definition: Marginal zone lymphoma (MZL) encompasses a group of slow-growing B-cell lymphomas that originate in the marginal zone of lymphoid tissues. The three main subtypes are extranodal MZL (MALT lymphoma), nodal MZL, and splenic MZL. Symptoms vary depending on the subtype and the affected area.

How to Differentiate Other Types of MZL from Splenic Marginal Zone Lymphoma: While SMZL specifically affects the spleen, extranodal MZL often involves organs such as the stomach or lungs, causing symptoms like abdominal pain or gastrointestinal bleeding, which are uncommon in SMZL. Nodal MZL primarily affects lymph nodes, leading to more pronounced lymph node swelling than in SMZL. Blood tests, imaging studies, and biopsies of affected tissues are essential for distinguishing between these types. Extranodal MZL may show organ-specific abnormalities, while SMZL involves abnormal cells concentrated in the spleen and bone marrow.

Hairy Cell Leukemia

Definition: Hairy cell leukemia is a rare, slow-growing blood cancer that affects B-lymphocytes. It is named for the “hairy” appearance of abnormal cells under a microscope. This condition leads to the accumulation of these cells in the bone marrow, spleen, and blood, causing symptoms such as fatigue, frequent infections, and splenomegaly.

How to Differentiate Hairy Cell Leukemia from Splenic Marginal Zone Lymphoma: Both hairy cell leukemia and SMZL can cause splenomegaly and low blood counts (anemia, low platelets, or low white blood cells). However, hairy cell leukemia is distinguished by the “hairy” appearance of abnormal cells under a microscope, which is not seen in SMZL. Hairy cell leukemia also tends to involve more severe bone marrow suppression, leading to pronounced pancytopenia. Flow cytometry can identify markers such as CD103 and CD25, which are present in hairy cell leukemia but absent in SMZL.

Lymphoma (General)

Definition: Lymphoma refers to cancers that originate in the lymphatic system, a key part of the immune system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Symptoms often include swollen lymph nodes, fever, night sweats, and unexplained weight loss, though specific symptoms and prognosis vary depending on the type and stage.

How to Differentiate Lymphoma from Splenic Marginal Zone Lymphoma: As a subtype of non-Hodgkin lymphoma, SMZL shares symptoms such as swollen lymph nodes, fatigue, and splenomegaly with other lymphomas. However, SMZL primarily affects the spleen, while other lymphomas often involve widespread lymph node enlargement or other organs. A biopsy of the spleen or lymph nodes is necessary to confirm the specific type. In SMZL, abnormal cells are concentrated in the spleen and bone marrow, whereas other lymphomas display different patterns of involvement. Blood tests, imaging studies, and genetic testing can further help differentiate lymphoma types.

Autoimmune Lymphoproliferative Syndrome (ALPS)

Definition: Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder that affects the immune system. It leads to excessive lymphocyte production, resulting in enlarged lymph nodes, spleen, and liver. ALPS is also associated with autoimmune complications, such as anemia, low platelet counts, and frequent infections.

How to Differentiate ALPS from Splenic Marginal Zone Lymphoma: Both ALPS and SMZL can cause splenomegaly and low blood counts, but ALPS often presents with autoimmune symptoms like hemolytic anemia and thrombocytopenia, which are less common in SMZL. ALPS typically manifests in childhood or early adulthood, whereas SMZL is more common in older adults. Genetic testing can confirm ALPS by identifying mutations in genes such as FAS, which are not involved in SMZL. A biopsy of the spleen or lymph nodes may also reveal distinct patterns of abnormal cell growth in ALPS compared to SMZL.

Infectious Mononucleosis

Definition: Infectious mononucleosis, commonly known as “mono,” is a viral infection caused by the Epstein-Barr virus (EBV). It is most prevalent among teenagers and young adults and spreads through saliva. Symptoms include fatigue, fever, sore throat, swollen lymph nodes, and splenomegaly.

How to Differentiate Infectious Mononucleosis from Splenic Marginal Zone Lymphoma: Both mono and SMZL can cause splenomegaly and swollen lymph nodes. However, mono typically includes symptoms such as sore throat, fever, and fatigue, which are less common in SMZL. Blood tests for mono often reveal atypical lymphocytes and positive EBV antibodies, while SMZL involves cancerous lymphocytes and no viral infection. A biopsy of the spleen or lymph nodes may be required to confirm SMZL if the diagnosis remains uncertain.

Splenic Abscess

Definition: A splenic abscess is a rare condition in which a pocket of pus forms in the spleen due to infection. It is often caused by bacteria, fungi, or parasites and typically occurs in individuals with weakened immune systems. Symptoms include fever, abdominal pain (especially in the upper left side), and splenomegaly.

How to Differentiate a Splenic Abscess from Splenic Marginal Zone Lymphoma: Both splenic abscesses and SMZL can cause splenomegaly and abdominal discomfort. However, splenic abscesses are usually accompanied by infection-related symptoms such as fever, chills, and localized pain, which are not typical of SMZL. Blood tests in splenic abscesses may show elevated white blood cell counts and infection markers like C-reactive protein (CRP), which are not elevated in SMZL. Imaging studies, such as CT scans, can identify abscesses, and a biopsy or drainage may confirm the diagnosis and identify the infectious organism.

Sarcoidosis

Definition: Sarcoidosis is an inflammatory disease that causes granulomas (clusters of immune cells) to form in various organs, most commonly the lungs and lymph nodes. Its exact cause is unknown, but symptoms often include fatigue, shortness of breath, and swollen lymph nodes. The spleen and liver may also be affected in some cases.

How to Differentiate Sarcoidosis from Splenic Marginal Zone Lymphoma: Both sarcoidosis and SMZL can cause splenomegaly, swollen lymph nodes, and fatigue. However, sarcoidosis more commonly affects the lungs, leading to symptoms such as shortness of breath and persistent cough, which are not typical of SMZL. Blood tests in sarcoidosis may show elevated calcium levels and inflammatory markers like ESR, which are not seen in SMZL. A biopsy can confirm sarcoidosis by identifying granulomas, while SMZL involves abnormal lymphocytes.

Myelodysplastic Syndromes (MDS)

Definition: Myelodysplastic syndromes (MDS) are a group of disorders caused by poorly functioning bone marrow, resulting in low blood cell counts. Symptoms include fatigue, frequent infections, and easy bruising or bleeding. MDS can sometimes progress to acute leukemia.

How to Differentiate MDS from Splenic Marginal Zone Lymphoma: Both MDS and SMZL can cause low blood counts, leading to fatigue and frequent infections. However, MDS is primarily a bone marrow disorder, while SMZL primarily affects the spleen. A bone marrow biopsy is crucial for diagnosing MDS, as it reveals abnormal, immature blood cells and impaired blood cell production. In contrast, SMZL involves abnormal lymphocytes in the spleen and bone marrow. Genetic testing may identify mutations in MDS, such as TP53, which are not typically seen in SMZL.

Conclusion: Understanding and Managing Splenic Marginal Zone Lymphoma

Splenic marginal zone lymphoma (SMZL) is a rare form of non-Hodgkin lymphoma that primarily affects the spleen and bone marrow. Early diagnosis plays a crucial role in managing this condition effectively and improving patient outcomes. By recognizing the symptoms of lymphoma and seeking timely medical care, you can significantly influence the course of the disease.

Thankfully, there are several effective treatment options available for splenic marginal zone lymphoma. These include medications such as rituximab and advanced targeted therapies like ibrutinib, which have shown encouraging results. Many patients achieve remission and maintain a high quality of life with these treatments. Additionally, personalized treatment plans tailored to each individual’s unique needs can further enhance the success of therapy.

Seek Expert Care for Splenic Marginal Zone Lymphoma

If you or someone you care about has been diagnosed with splenic marginal zone lymphoma, consulting a medical professional without delay is essential. Early intervention not only helps manage the condition more effectively but also increases the chances of achieving long-term remission. Gaining a clear understanding of the symptoms and exploring the available treatment options empowers you to make well-informed decisions about your care.

Our telemedicine practice provides convenient access to expert care for individuals diagnosed with splenic lymphoma or other types of non-Hodgkin lymphoma. With personalized treatment plans and the ability to consult specialists from the comfort of your home, we are committed to making the management of your condition as straightforward and supportive as possible. Contact us today for guidance and assistance on your journey toward improved health and well-being.

James Kingsley

Learn More